Table 8 SUCRA
Interventions | QMG | MGC | MG-ADL | MG-QoL 15r | ||||
|---|---|---|---|---|---|---|---|---|
SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | |
Placebo | 17.4 | 9 | 20.5 | 8 | 18.1 | 8 | 17.8 | 6 |
Batoclimab | 83.4 | 1 | 74.5 | 1 | 5 | 9 | 67.1 | 3 |
Efgartigimod | 46.9 | 7 | 42.5 | 6 | 41.8 | 7 | 32.4 | 5 |
Rituximab | 47.3 | 6 | 48 | 5 | 43.9 | 6 | 14.1 | 7 |
Rozanolixizumab | 31.8 | 8 | 51.4 | 4 | 54.5 | 5 | Â | Â |
Belimumab | 53.8 | 4 | 31.4 | 7 | 88.5 | 1 | Â | Â |
Zilucoplan | 57.4 | 3 | 62.7 | 3 | 71.7 | 2 | 77.6 | 2 |
Eculizumab | 62.2 | 2 | 69.1 | 2 | 64 | 3 | 93.7 | 1 |
Ravulizumab | 49.7 | 5 | Â | Â | 62.5 | 4 | 47.2 | 4 |